Alzheimer’s PET Coverage Decision Stalls At HHS; Limited Indication Ahead?
This article was originally published in The Gray Sheet
Executive Summary
HHS Secretary Tommy Thompson will convene an expert panel to help CMS define the patient population for which PET imaging is an appropriate test for Alzheimer's disease, according to Senate staffers
You may also be interested in...
PET Community Coalesces For Alzheimer’s Disease Diagnosis Coverage
Reimbursement of positron emission tomography for diagnosing Alzheimer's disease will be contingent on the PET community's mobilization and grassroots efforts, according to Rep. Nancy Johnson (R-Conn.)
PET Community Coalesces For Alzheimer’s Disease Diagnosis Coverage
Reimbursement of positron emission tomography for diagnosing Alzheimer's disease will be contingent on the PET community's mobilization and grassroots efforts, according to Rep. Nancy Johnson (R-Conn.)
Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS
CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases